Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2016; 22(42): 9288-9299
Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9288
Glycoproteins and glycoproteomics in pancreatic cancer
Sheng Pan, Teresa A Brentnall, Ru Chen
Sheng Pan, Teresa A Brentnall, Ru Chen, Department of Medicine, University of Washington, Seattle, WA 98195, United States
Author contributions: Pan S wrote the manuscript; Chen R and Brentnall TA reviewed and contributed to the manuscript.
Conflict-of-interest statement: The authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Sheng Pan, PhD, Department of Medicine, University of Washington, 1959 NE Pacific St., Seattle, WA 98195, United States.
Telephone: +1-206-6853632 Fax: +1-206-6859478
Received: June 29, 2016
Peer-review started: June 30, 2016
First decision: August 8, 2016
Revised: August 23, 2016
Accepted: September 14, 2016
Article in press: September 14, 2016
Published online: November 14, 2016
Core Tip

Core tip: Protein glycosylation plays an important role in pancreatic tumorigenesis. Malignance induced changes in protein glycosylation can profoundly impact the function of a protein in multiple ways. One approach for developing better diagnostic and therapeutic strategies in pancreatic cancer involves targeting cancer-associated aberrant glycosylation. This review discusses the recent discoveries in glycoproteomics study of pancreatic cancer.